SWOG clinical trial number
SWOG-9308

Randomized Trial Comparing Cisplatin With Cisplatin Plus Intravenous Navelbine® in the Treatment of Previously Untreated, Stage IV Non-Small Cell Lung Cancer Patients

Closed
Phase
III
Accrual
98%
Published
Abbreviated Title
Randomized Trial Comparing Cisplatin With Cisplatin Plus Intravenous Navelbine® in the Treatment of Previously Untreated, Stage IV Non-Small Cell Lung Cancer Patients
Activated
10/15/1993
Closed
06/01/1995

Research committees

Lung Cancer

Publication Information Expand/Collapse

2018

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

The association between ASCO Value framework and scientific and clinical impact of SWOG phase III clinical trials

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster

Survival by Hispanic Ethnicity Among Cancer Patients participating in SWOG Clinical Trials

A Moseley;M Chavez-MacGregor;J Unger;S Ramsey;D Hershman Society for Clinical Trials Annual Meeting (May 20-23 2018, Portland, OR), oral presentation

2017

The effect of positive SWOG treatment trials on survival of patients with cancer in the US population

JM Unger;M Leblanc;CD Blanke JAMA Oncology Oct 1;3(10):1345-1351

PMid: PMID28586789; PMC5710507

The impact of positive SWOG treatment trials on population survival

J Unger;M LeBlanc;C Blanke J Clin Oncol 35, 2017 (suppl; abstr 6513); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion

A Clinical Prognostic Model for Survival of Elderly Patients with Non-Small Cell Lung Cancer

AK Ganti;X Wang;TE Stinchcombe;YA Wang;K Kelly;R Paulus;JD Bradley;S Ramalingam;H Cohen;E Vokes;H Pang IASLC World Conference on Lung Cancer (October 15 - 18 2017, Yokohama, Japan), accepted, oral

2014

Comparison of survival outcomes among cancer patients treated in and out of clinical trials

J Unger;W Barlow;DP Martin;S Ramsey;M Leblanc;R Etzioni;D Hershman Journal of the National Cancer Institute 106(3):dju002; 2014 Mar 13 [Epub ahead of print];

PMid: PMID24627276 | PMC number: PMC3982777

Association between BMI at treatment initiation and cancer survival across multiple SWOG trials

H Greenlee;J Unger;M Leblanc;D Hershman AACR Research International Conference on Frontiers on Cancer Research Prevention (Sept 28-Oct 1, 2014, New Orleans, LA; poster

2013

Chemotherapy outcomes by histological subtypes of non-small cell lung cancer: analysis of the SWOG database for antimicrotubule-platinum therapy

K Kelly;K Chansky;P Mack;P Lara;FR Hirsch;WA Franklin;A Wozniak;MJ Edelman;SK Williamson;DR Gandara Clinical Lung Cancer 14(6):627-635;

PMid: PMID23910067 | PMC number: PMC4122504

Modeling the relationship between progression-free survival and overall survival: the phase 2/3 trial

M Redman;B Goldman;M LeBlanc;A Schott;LH Baker Clinical Cancer Research, 19(10):2646-2656;

PMid: PMID23669424 | PMC number: PMC4131693

2009

Racial disparities in survival of patients with sex-specific cancers treated on Southwest Oncology Group clinical trials. PMC2724852; PMID: 19584328

KS Albain;JM Unger;JJ Crowley;CA Coltman;DL Hershman Journal of the National Cancer Institute 101(14):984-992

Chemotherapy outcomes by histologic subtype of non-small cell lung cancer (NSCLC): analysis of the SWOG database for antimicrotubule-platinum therapy

K Chansky;PC Mack;J Crowley;PN Lara;FR Hirsch;WA Franklin;DR Gandara Journal of Thoracic Oncology 4(9);suppl 1, abst. #B2.7, S326;

Minority report: how best to analyze clinical trial data to address disparities

D Hershman;J Unger Breast Cancer Research and Treatment 118:519-521

2008

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

2007

Toxicity and survival by sex in patients with advanced non small cell lung carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials.

KS Albain;JM Unger;CC Gotay;AM Davies;M Edelman;RS Herbst;K Kelly;SK Williamson;AJ Wozniak;DR Gandara Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#7549

2001

Should older patients (PTS) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? an analysis of Southwest Oncology trials 9509 and 9308.

K Kelly;S Giarritta;S Hayes;W Akerley;P Hesketh;A Wozniak;K Albain;J Crowley;DR Gandara Proc of the American Society of Clinical Oncology 20:329a(#1313)

1998

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study.

AJ Wozniak;JJ Crowley;SP Balcerzak;GR Weiss;CH Spiridonidis;LH Baker;KS Albain;K Kelly;SA Taylor;DR Gandara;RB Livingston Journal of Clinical Oncology 16(7):2459-2465

Randomized phase III trial of cisplatin (CDDP) vs CDDP plus navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): An update of a Southwest Oncology Group study (SWOG 9308).

AJ Wozniak;JJ Crowley;SP Balcerzak;GR Weiss;CH Spiridonidis;LH Baker;KS Albain;K Kelly;SA Taylor;DR Gandara;RB Livingston Proc of the American Society of Clinical Oncology 17:453a(#1744)

1996

Randomized phase III trial of cisplatin (CDDP) vs. CDDP plus navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): Report of a Southwest Oncology Group study (SWOG-9308).

AJ Wozniak;JJ Crowley;SP Balcerzak;GR Weiss;LR Laufman;LH Baker;RI Fisher;SI Bearman;SA Taylor;RB Livingston American Society of Clinical Oncology 15:374(#111)